ATRO Medical B.V. is an innovative medical device company that was founded in 2016. The first product under development is the Trammpolin® meniscus prosthesis. The meniscus is an important shock absorber in the knee joint. Damage and wear of the meniscus are important causes of osteoarthritis of the knee. Trammpolin® intends to replace the damaged meniscus, with the aim of restoring the shock absorbing function of the meniscus by acting as a joint spacer. The company is addressing a large unmet medical need, as the number of patients with knee pain caused by a meniscectomy increase. These patients gradually develop osteoarthritis, resulting in pain and reduced mobility. Current treatment options for these patients are limited with distinct drawbacks. The Trammpolin® meniscus prosthesis aims to provide a cost-effective solution for meniscus replacements and to fill the gap in treatment options between meniscus tear surgical repair and total knee replacement.
Dr. Hunik graduated at the University of Wageningen, where he also obtained his PhD on bioprocess technology. After which he started working at Unilever for four years as project manager biotechnology. Next, he worked at DSM where he fulfilled several roles in B2B marketing and innovation, where he developed patented technology into commercial products. From 2010-2016, he worked as director of strategy at DSM Biomedical Materials. In 2016, he co-founded ATRO Medical, and he acts as CEO ever since. He is responsible for the project management, attracting investors, team building and the financial management.
Dr. van Tienen graduated as a medical doctor from the Radboudumc in 1998. He obtained his PhD in 2004 at the Radboudumc on ‘in vivo engineering of knee joint meniscus’. He has over 10 years’ experience as orthopaedic knee surgeon and over 20 years’ experience in meniscus research. He published over 30 publications on the meniscus and meniscus prostheses. He has an active research line at the Radboudumc on the development of meniscus prostheses. In 2016 he co-founded ATRO Medical, and acts as CMO ever since. He is responsible for the medical research, partnerships with medical institutions and the development of the surgical procedure.
Mr. Pikaart obtained his bachelor’s degree in Mechanical Engineering and his master’s degree in Biomedical Engineering at the Eindhoven University of Technology, in respectively 2004 and 2008. After graduating, he moved into the medical device industry where he fulfilled multiple clinical and regulatory positions at Medpace Medical Device B.V. for 10 years in which he build in-depth experience in project and operational management, clinical research, and regulatory affairs. In November 2017, he started as Clinical Research Director at Atro Medical, where he is responsible for the clinical strategy, regulatory submissions for marketing authorizations in the EU and the US, and the design, management and execution of the clinical study programs.
Mr. van Minnen obtained his Bachelor and Master’s degree in Biomedical Engineering from the University of Twente, in respectively 2012 and 2015. His Master Thesis entitled: Predicting gait using a patient-specific musculoskeletal model of patients with hip dysplasia. From 2015 to 2017 he worked as a research scientist in the Orthopaedic Research Lab of the Radboudumc, as part of the BMM2 Trammpolin project. In April 2017, he started working at ATRO Medical where he is currently involved in the design and preclinical testing of the Trammpolin® meniscus prosthesis, as well as the company’s quality management.
Mrs. Brinks has a medical background as certified clinical perfusionist. She worked as clinical perfusionist at Erasmus MC and Radboudumc, where she also did research on anticoagulation during cardiac surgery. She studied Management Sciences and has over 15 years’ experience in the medical device industry in various management and board positions covering disciplines like sales, manufacturing, business development, among others at Medtronic and Indes.
In December 2017, she started as Operations Manager at ATRO Medical, where she is responsible for selection and contracting of suppliers, outsourcing of production, purchasing, production planning and quality of the delivered products.
Mrs. Lugies is a registered nurse and with her medical background has accumulated an extensive knowledge in the execution of clinical study programs, and user training & device support. In the past 15 years she has been working for multiple start-up companies developing meniscus prosthesis solutions by managing numerous European multicenter studies, from First In Man until Post Market Clinical Follow Up. In June 2018, she joined ATRO Medical as Clinical Field Director, where she is responsible for providing training and technical support in the clinical use of the Trammpolin® meniscus prosthesis and contributes to the management and execution of clinical studies and programs.
Dr.ir. van der Veen graduated at the department of Mechanical Engineering at Delft University of Technology. After which he started working at Fokker Aircraft in the flight controls group. Next, he worked at Fokker Space B.V. as specialist structural integrity. From 2000 he worked at the department of Physics and Medical Technology at The VU University Medical Center where he obtained his PhD on mechanics of the spine. In the lab he gained a lot of experience in the field of in vitro biomechanical testing.
At the start of 2019 he started as senior scientist at ATRO Medical where he is involved in biomechanical testing of the Trammpolin® meniscus prosthesis.
Mr. van der Zanden graduated as biomedical engineer at the University of Twente in 2007. Since then he has been involved in medical innovations. He started as product developer in orthopedics and later on specialized in the field of biomedical marketing. Between 2011 and 2019, he has worked in commercial positions in radiotherapy and in vitro diagnostics, such as Commercial Director at a start-up laboratory.
In May 2019, he has joined ATRO Medical as Market Development Manager, where he is responsible for the market entry of the Trammpolin® meniscus prosthesis. He will work closely with the many stakeholders involved in this process.